{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["White MN"],"funding":["NCI NIH HHS"],"pagination":["e210-e221"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12779337"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(3)"],"pubmed_abstract":["<h4>Introduction</h4>Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown.<h4>Materials and methods</h4>This was a retrospective analysis at 2 university-affiliated institutions. Patients with EGFR-mutant lung cancer who had progression on osimertinib and received next-line therapy with platinum doublet chemotherapy (chemo), platinum doublet chemotherapy plus immunotherapy (chemo-IO), or platinum doublet chemotherapy plus bevacizumab (chemo-bev), were identified; patients who continued osimertinib with these regimens were included. Efficacy outcomes including duration on treatment (DOT) and overall survival (OS) from the sta"],"journal":["Clinical lung cancer"],"pubmed_title":["Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib."],"pmcid":["PMC12779337"],"funding_grant_id":["P30 CA124435"],"pubmed_authors":["Piper-Vallillo AJ","Cunanan K","Sequist LV","Neal JW","White MN","Padda SK","Ramchandran K","Gardner RM","Chen TT","Piotrowska Z","Wakelee HA","Das M"],"additional_accession":[]},"is_claimable":false,"name":"Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.","description":"<h4>Introduction</h4>Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown.<h4>Materials and methods</h4>This was a retrospective analysis at 2 university-affiliated institutions. Patients with EGFR-mutant lung cancer who had progression on osimertinib and received next-line therapy with platinum doublet chemotherapy (chemo), platinum doublet chemotherapy plus immunotherapy (chemo-IO), or platinum doublet chemotherapy plus bevacizumab (chemo-bev), were identified; patients who continued osimertinib with these regimens were included. Efficacy outcomes including duration on treatment (DOT) and overall survival (OS) from the sta","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-06-06T12:46:06.371Z","creation":"2026-05-30T03:11:40.11Z"},"accession":"S-EPMC12779337","cross_references":{"pubmed":["34887193"],"doi":["10.1016/j.cllc.2021.11.001"]}}